Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample
- PMID: 28719885
- PMCID: PMC5557040
- DOI: 10.1016/j.drugalcdep.2017.06.009
Racial and ethnic differences in opioid agonist treatment for opioid use disorder in a U.S. national sample
Abstract
Background: Opioid Agonist Treatment (OAT) is the standard of care for the treatment of opioid use disorders. However, most people in treatment do not receive OAT. This study evaluated whether there are racial and/or ethnic differences in OAT receipt among adults entering specialty treatment for opioid use disorders in publicly-funded treatment programs across the U.S.
Methods: Using data from the national Treatment: Episode Data Base, odds of OAT receipt were compared among black, Hispanic and white clients. Mediation analyses were used to explore whether any racial/ethnic differences in OAT receipt were explained by variation in clinical need or by other treatment, sociodemographic, or geographic characteristics. Interaction terms were used to assess whether this association was modified by primary opioid type.
Results: Only 28.7% of clients received OAT. Odds of OAT receipt were significantly higher odds among blacks (OR: 2.27(2.14-2.41)) and Hispanics (OR: 1.98(1.88-2.09)), compared to whites. Differences in clinical need accounted for a substantial portion of this difference (76.79% and 49.74%, respectively). Differences persisted after accounting for other potential explanatory variables (adjusted OR: 1.37 (1.24-1.52); 1.21(1.11-1.32)), but were only evident for primary heroin users (adjusted OR: 1.50 (1.34-1.69); 1.29 (1.17-1.42)) and not other opioid users.
Conclusions: OAT receipt in treatment programs is low overall and particularly lacking among white heroin users. Differences in OAT receipt cannot be fully explained by differences in clinical need. More research is needed to understand and address barriers that underpin these differences so more patients with opioid use disorder can access evidenced-based treatment.
Keywords: Ethnic minorities; Medication assisted treatment; Opioid agonist treatment; Opioid treatment programs; Opioid use disorder; Racial disparities.
Copyright © 2017 Elsevier B.V. All rights reserved.
Conflict of interest statement
No conflict declared.
Similar articles
-
Racial/ethnic differences in prescription opioid misuse and heroin use among a national sample, 1999-2018.Drug Alcohol Depend. 2021 Apr 1;221:108588. doi: 10.1016/j.drugalcdep.2021.108588. Epub 2021 Feb 13. Drug Alcohol Depend. 2021. PMID: 33639569 Free PMC article.
-
Exploring racial and secondary substance use differences in route of administration of opioid drugs: Analysis of the 2015-2019 treatment admission data.J Subst Use Addict Treat. 2024 Jul;162:209365. doi: 10.1016/j.josat.2024.209365. Epub 2024 Apr 16. J Subst Use Addict Treat. 2024. PMID: 38626850
-
Racial Inequality in Receipt of Medications for Opioid Use Disorder.N Engl J Med. 2023 May 11;388(19):1779-1789. doi: 10.1056/NEJMsa2212412. N Engl J Med. 2023. PMID: 37163624 Free PMC article.
-
Racial Disparities in Payment Source of Opioid Use Disorder Treatment among Non-Incarcerated Justice-Involved Adults in the United States.J Ment Health Policy Econ. 2020 Mar 1;23(1):19-25. J Ment Health Policy Econ. 2020. PMID: 32458814
-
Racial/Ethnic Differences in Prevalence Trends for Heroin use and Non-Medical use of Prescription Opioids Among Entrants to Opioid Treatment Programs, 2005-2016.Subst Use Misuse. 2018 Jan 28;53(2):290-300. doi: 10.1080/10826084.2017.1334070. Epub 2017 Aug 30. Subst Use Misuse. 2018. PMID: 28854060
Cited by
-
First-hand accounts of structural stigma toward people who use opioids on Reddit.Soc Sci Med. 2024 Apr;347:116772. doi: 10.1016/j.socscimed.2024.116772. Epub 2024 Mar 16. Soc Sci Med. 2024. PMID: 38502980
-
Receipt and duration of buprenorphine treatment during pregnancy and postpartum periods in a national privately-insured cohort.Drug Alcohol Depend Rep. 2023 Nov 10;9:100206. doi: 10.1016/j.dadr.2023.100206. eCollection 2023 Dec. Drug Alcohol Depend Rep. 2023. PMID: 38045493 Free PMC article.
-
Application of an Opioid Use Disorder Cascade of Care in a Large Public Health System.medRxiv [Preprint]. 2023 Oct 19:2023.10.19.23297271. doi: 10.1101/2023.10.19.23297271. medRxiv. 2023. Update in: Am J Drug Alcohol Abuse. 2024 Mar 3;50(2):181-190. doi: 10.1080/00952990.2024.2302500 PMID: 37905052 Free PMC article. Updated. Preprint.
-
Racial and Ethnic Inequities in Buprenorphine and Methadone Utilization Among Reproductive-Age Women with Opioid Use Disorder: an Analysis of Multi-state Medicaid Claims in the USA.J Gen Intern Med. 2023 Dec;38(16):3499-3508. doi: 10.1007/s11606-023-08306-0. Epub 2023 Jul 12. J Gen Intern Med. 2023. PMID: 37436568 Free PMC article.
-
Technical violations and infractions are drivers of disengagement from methadone treatment among people with opioid use disorder discharged from Connecticut jails 2014-2018.Subst Abuse Treat Prev Policy. 2023 Jul 7;18(1):43. doi: 10.1186/s13011-023-00541-2. Subst Abuse Treat Prev Policy. 2023. PMID: 37420271 Free PMC article.
References
-
- Alegría M, Page JB, Hansen H, Cauce AM, Robles R, Blanco C, Cortes DE, Amaro H, Morales A, Berry P. Improving drug treatment services for hispanics: Research gaps and scientific opportunities. Drug Alcohol Depend. 2006;84:S76–S84. - PubMed
-
- Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the united states: A retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71:821–826. - PubMed
-
- Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374:154–163. - PubMed
-
- Connery HS. Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions. Harv Rev Psychiatry. 2015;23:63–75. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
